Drug Profile
Research programme: peroxisome proliferator-activated receptor delta therapeutics - Reneo Pharmaceuticals/vTv Therapeutics
Latest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator vTv Therapeutics LLC
- Class Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 13 Nov 2023 Reneo Pharmaceuticals receives notice of allowance from the USPTO for use of PPAR-delta agonists
- 28 Jan 2022 No recent reports of development identified for research development in Unspecified in USA (PO)
- 21 Dec 2017 Peroxisome proliferator-activated receptor delta therapeutics licensed to Reneo Pharmaceuticals worldwide